Skip to main content
. 2019 Jan 31;139(15):1798–1812. doi: 10.1161/CIRCULATIONAHA.118.036053

Figure 2.

Figure 2.

Splenectomy abolishes the therapeutic effects of POL5551. A, Experimental setup. Myocardial infarction (MI) was induced in wild-type (WT) mice. Additional mice underwent sham surgery. POL5551 (POL) or vehicle only (control) was intraperitoneally injected 2, 4, 6, and 8 days after MI. Infarcted mice underwent splenectomy (SPX) immediately before the first injection. B, Fluorescein-labeled isolectin B4 (IB4)+ capillary density in infarct border zone 28 days after MI; 6 mice per group. CM indicates cardiomyocyte. C, Scar size 28 days after MI; 14 mice per group. D and E, 20 sham-operated mice, 19 control mice, 19 POL5551-treated mice. D, LVEDA and LVESA as determined by echocardiography 28 days after sham surgery or MI. LVEDA and LVESA: P<0.001, MI vs sham for both treatment groups (2-way ANOVA with Tukey post hoc test). E, Fractional area change (FAC). ***P<0.001 vs both MI groups (2-way ANOVA with Tukey post hoc test). Con indicates control; Echo, echocardiography; LV, left ventricular; LVEDA, left ventricular end-diastolic area; and LVESA, left ventricular end-systolic area.